Paper Details

  1. Home
  2. Paper Details

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Author: , BlaisJaime D, ChapmanArlene B, CzerwiecFrank S, DevuystOlivier, GansevoortRon T, KochGary, McQuadeRobert D, OuyangJohn, PerroneRonald D, SergeyevaOlga, TorresVicente E

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tolvaptan, a vasopressin V2-receptor antagonist, has been shown to slow the progression of autosomal dominant polycystic kidney disease (ADPKD) in early stages. This abstract highlights the need for further research to evaluate its efficacy and safety in patients with later-stage ADPKD.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND">In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, &#8805;60 ml per minute), the vasopressin V<sub>2</sub>-receptor antagonist tolvaptan slowed the growth in total kidney volume and the decline in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1710030

データ提供：米国国立医学図書館（NLM）

Tolvaptan: A Potential Oasis for Later-Stage Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that causes cysts to grow in the kidneys, ultimately leading to kidney failure. This abstract explores the potential of tolvaptan, a vasopressin V2-receptor antagonist, as a treatment option for patients with later-stage ADPKD. It's like seeking a hidden oasis of hope in the desert of ADPKD. Previous studies have shown that tolvaptan can slow the progression of ADPKD in early stages, but its effectiveness in later stages was unknown.

This abstract highlights the need for further research to determine the efficacy and safety of tolvaptan in patients with later-stage ADPKD. It's like venturing deeper into the desert of ADPKD, seeking new pathways to manage this complex disease.

A New Oasis in the Desert of ADPKD Research

This research presents a promising avenue for exploring treatment options for later-stage ADPKD, a disease that often leads to kidney failure. It's like finding a hidden spring in the desert of ADPKD research, offering a potential source of relief for patients. This abstract emphasizes the importance of continued research to determine the true potential of tolvaptan in managing this challenging condition.

Impact on Healthcare and Life

This research offers a glimmer of hope for patients with later-stage ADPKD, a disease that can significantly impact quality of life. It's like finding a hidden oasis in the desert of ADPKD, providing a source of potential for better treatment options. This study underscores the importance of continued research to improve the lives of patients living with this challenging condition.

Dr. Camel's Conclusion

This research is like a camel caravan trekking through the desert of ADPKD research, searching for a solution for those with later-stage disease. It shows us that we need to keep looking for new treatments, so we can provide the best possible care for patients. Keep those research camels trekking across the desert, we need more discoveries like this one!

Date :
  1. Date Completed 2017-12-01
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

29105594

DOI: Digital Object Identifier

10.1056/NEJMoa1710030

Related Literature

Article Analysis
・Side Effects of tolvaptan (kidney disease)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.